Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional
Official Title: Phase IIa Study of the Efficacy of Single Agent BGJ398 in FGFR1-3 Translocated, Mutated, or Amplified Squamous Cell Carcinoma of the Head and Neck
Brief Summary: This phase IIa trial studies how well pan fibroblast growth factor receptor (FGFR) kinase inhibitor BGJ398 works in treating patients with FGFR1-3 translocated, mutated, or amplified head and neck cancer that has returned after a period of improvement. Pan FGFR kinase inhibitor BGJ398 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.